Skip to main content
Publications
Herring WL , Gallagher ME, Shah N, Morse KC, Mladsi D , Dong OM , Chawla A, Leiding JW, Zhang L, Paramore C, Andemariam B. Cost-effectiveness of lovotibeglogene autotemcel (lovo-cel) gene therapy for patients with sickle cell disease and recurrent vaso-occlusive events in the United States . Pharmacoeconomics. 2024 Apr 29. doi: 10.1007/s40273-024-01385-9
Duran CE, Riera-Arnau J, Abtahi S, Pajouheshnia R , Hoxhaj V, Gamba M, Alsina E, Martin-Perez M, Garcia-Posa P, Llorente-Garcia A, Gonzalez-Bermejo D, Ibanez L, Sabate M, Vidal X, Ballarin E, Sanfelix-Gimeno G, Rodriguez-Bernal C, Peiro S, Garcia-Sempere A, Sanchez-Saez F, Lentile V, Ingrasciotta Y, Guarneri C, Tanaglia M, Tari M, Herings R, Houben E, Swart-Polinder K, Holthuis E, Huerta C, Gini R, Roberto G, Bartolini C, Paoletti O, Limoncella G, Girardi A, Hyeraci G, Andersen M, Kristiansen SB, Hallgreen CE, Klungel O, Sturkenboom M. Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Netherlands, and Spain: an interrupted time series analysis . Front Pharmacol. 2023 Aug 17;14:1207976. doi: 10.3389/fphar.2023.1207976
Abdulkareem NM, Bhat R, Powell RT, Chikermane S, Yande S , Trinh L, Abdelnasser HY, Tabassum M, Ruiz A, Sobieski M, Nguyen ND, Johnson M, Kaipparettu BA, Johnson CA, Bond RA, Stephan C, Triveni MV. Screening of GPCR drugs for repurposing in breast cancer . Front Pharmacol. 2022 Dec 6;13:1049640. doi: 10.3389/fphar.2022.1049640
Spelman T, Herring WL , Zhang Y, Tempest M, Pearson I , Freudensprung U, Acosta C, Dort T, Hyde R, Havrdova E, Horakova D, Trojano M, De Luca G, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Alroughani R, Pucci E, Granella F, Lechner-Scott J, Sola P, Ferraro D, Grand’Maison F, Terzi M, Rozsa C, Boz C, Hupperts R, Van Pesch V, Oreja-Guevara C, van der Walt A, Jokubaitis VG, Kalincik T, Butzkueven H. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in the United Kingdom . Pharmacoeconomics. 2022 Mar;40(3):323-39. doi: 10.1007/s40273-021-01106-6.
Paquette M, Franca LR, Teutsch C, Diener HC, Lu S, Dubner SJ, Ma CS, Rothman KJ , Zint K, Halperin JL, Olshansky B, Huisman MV, Lip GYH, Nieuwlaat R. Dabigatran persistence and outcomes following discontinuation in atrial fibrillation patients from the GLORIA-AF registry . Am J Cardiol. 2020 Feb 1;125(3):383-91. doi: 10.1016/j.amjcard.2019.10.047
Ribera A, Ferreira-Gonzalez I, Marsal JR , Cascant P, Permanyer-Miralda G, Abdul-Jawad O, Inigo-Garcia LA, Guarinos-Oltra J, Cequier A, Goicolea-Guemez L, Garcia-Del-Blanco B, Marti G, Garcia-Dorado D. Prognostic value of an abnormal ankle-brachial index in patients receiving drug-eluting stents . Am J Cardiol. 2011 Nov 1;108(9):1225-31. doi: 10.1016/j.amjcard.2011.06.036